We provide molecular insights into the diverse TCE strategies being employed against PCa (targeting PSMA, STEAP1, and DLL3), critically evaluate their associated clinical outcomes, and synthesize the lessons learned thus far. Here, DLL3 is linked to posterior cortical atrophy.